Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions

Please note: On April 3, 2020, the Food and Drug Administration approved luspatercept for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). View the full listing here.